Apixaban Market Report 2026

The apixaban market size has grown strongly in recent years. It will grow from $3.16 billion in 2025 to $3.43 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to growing prevalence of atrial fibrillation, increased awareness of stroke prevention, availability of generic anticoagulants, expansion of hospital infrastructure, advancements in diagnostic technologies.

The apixaban market size is expected to see strong growth in the next few years. It will grow to $4.61 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to rising geriatric population, growing demand for minimally invasive surgeries, integration of digital health monitoring, innovation in oral anticoagulant formulations, expansion of homecare services. Major trends in the forecast period include increasing adoption of direct oral anticoagulants (doacs), rising incidence of cardiovascular disorders, expansion of post-surgical thromboprophylaxis programs, development of patient-centric anticoagulation therapies, growth in outpatient and homecare anticoagulant management.

The increasing incidence of cardiovascular disease is poised to fuel apixaban market expansion in the years ahead. Cardiovascular disease includes various disorders impacting the heart and blood vessels, such as coronary artery disease, stroke, and heart failure. This surge stems from sedentary lifestyles, unhealthy eating patterns, smoking, obesity, hypertension, diabetes, and aging demographics. Apixaban plays a key role in treating cardiovascular disease by lowering blood clot risks and preventing issues like stroke, deep vein thrombosis, and pulmonary embolism. For instance, in January 2024, the American Heart Association - a US-based nonprofit - reported 931,578 cardiovascular disease deaths, a slight rise of under 3,000 from the 928,741 recorded in 2023. Thus, the growing burden of cardiovascular disease propels apixaban market growth.

Major companies in the apixaban market are prioritizing innovative developments, like generic anticoagulant drugs, to enhance treatment affordability, expand patient access, and bolster their market competitiveness. These generic anticoagulant medicines serve as therapeutically equivalent versions that inhibit critical factors in the coagulation cascade to prevent blood clots, thus lowering the risk of stroke and other major cardiovascular incidents. For example, in February 2023, Zydus Lifesciences, a pharmaceutical firm based in India, secured final U.S. Food and Drug Administration (FDA) approval for its generic apixaban tablets in 2.5 mg and 5 mg doses, matching the strengths of the reference product Eliquis. This approval promotes broader access to affordable anticoagulant options throughout the U.S. market, aiding better patient outcomes for disorders including atrial fibrillation, deep vein thrombosis, and pulmonary embolism.

In July 2025, Bristol-Myers Squibb Company, a US-based biopharmaceutical firm that supplies apixaban and creates prescription drugs for severe illnesses, teamed up with Pfizer Inc. to launch a Direct-to-Patient service for Eliquis (apixaban). Through this collaboration, Bristol-Myers Squibb and Pfizer seek to draw on their strengths in drug development and patient access, merging Bristol-Myers Squibb’s knowledge in clinical care and safety with Pfizer’s broad distribution capabilities to deliver Eliquis straight to patients' homes, thereby boosting adherence to medication and better health results. Pfizer Inc. is a US-based pharmaceutical giant that researches, develops, and produces medicines and vaccines in numerous therapeutic fields.

Major companies operating in the apixaban market are Bristol-Myers Squibb Company, Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Hetero Drugs Ltd., Medichem S.A., Simson Pharma Limited, Aspen Pharmacare Holdings Limited, Daiichi Sankyo Company Limited, Fresenius Kabi AG, Centaur Pharmaceuticals Pvt. Ltd., Pinnacle Life Sciences Private Limited.

North America was the largest region in the apixaban market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the apixaban market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the apixaban market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the apixaban market by increasing the cost of imported active pharmaceutical ingredients (APIs) and packaging materials, leading to higher production costs for manufacturers. The segments most affected include tablets and capsules used for DVT and PE prevention, particularly in regions like North America and Europe that rely on API imports from Asia. While tariffs have raised costs, they have also encouraged local manufacturing and investment in domestic production capabilities, potentially improving supply chain resilience and supporting long-term market stability.

The apixaban market research report is one of a series of new reports that provides apixaban market statistics, including apixaban industry global market size, regional shares, competitors with a apixaban market share, detailed apixaban market segments, market trends and opportunities, and any further data you may need to thrive in the apixaban industry. This apixaban market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Apixaban is an oral anticoagulant drug from the class of direct oral anticoagulants (DOACs). It helps lower the risk of stroke and systemic embolism in people with nonvalvular atrial fibrillation, an irregular heart rhythm. Doctors prescribe apixaban to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to stop DVT - which may progress to PE - in patients recovering from hip or knee replacement surgery.

The primary dosage forms for apixaban include capsules and tablets. Capsules represent a dosage form in which the drug is contained within a gelatin shell intended for whole swallowing, enabling the capsule to break down in the digestive system and release the active ingredient. Apixaban medications serve purposes like treating deep vein thrombosis (DVT) and pulmonary embolism (PE) among end users including hospitals, home care settings, specialty clinics, and additional facilities.

The apixaban market consists of sales of generic drugs, oral tablets and blister packs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.